Progenics Pharmaceuticals

Long-Term Fears Curb Futures Run

wsj.com     Mar 12, 2008   8 related          

Stock futures retreated from early gains, as concerns about the efficacy of the Federal Reserve's $200 billion capital injection curbed earlier momentum. The Fed's moves did buoy overseas markets, with European markets trading sharply higher on financials while Asia also rose on banks.                    

comments

Premarket: Humana Deals Another Blow to Health Insurers (at The Wall Street Journal Online)

yahoo.com     Mar 12, 2008   56 related          

Yesterday, it was WellPoint. Shares of Aetna were down 6% in premarket action, while UnitedHealth Group dropped 11%, and WellPoint lost 3.2%, after losing 24% in trading yesterday. The sector was one of the few trouble spots in a surge yesterday that saw the Dow...                    

comments

Indications: U.S. stock futures steady to lower after big run-up

marketwatch.com     Mar 12, 2008   41 related          

U.S. stock futures on Wednesday point to a pause after the biggest one-day surge in more than five years, following a plan by the Federal Reserve and other central banks to allow banks and bond dealers to swap mortgage-backed securities that can't currently sell for highly liquid Treasurys that...                    

comments

Premarket Movers: Progenics Plunges

chron.com     Mar 12, 2008   1 related          

NEW YORK — Progenics Pharmaceuticals Inc. shares plunged in premarket trading Wednesday after a treatment in development with drug maker Wyeth showed disappointing late-stage trial results. ... Shares of Progenics fell $7.55, or 56 percent, to $6 before the bell. Digital...                    

comments

Progenics Pharmaceuticals, Inc. And Wyeth Provides Update On Phase 3 Clinical Trial Of...

pharmiweb.co.uk     Mar 12, 2008   3 related          

Previous Page Page 1 Next Page Progenics Pharmaceuticals, Inc. And Wyeth Provides Update On Phase 3 Clinical Trial Of Intravenous Methylnaltrexone For Postoperative Ileus 5:35am EDT Progenics Pharmaceuticals, Inc. and Wyeth's Wyeth Pharmaceuticals, a division of Wyeth...                    

comments

Euroscreen Wins Opposition Related to its CCR5 Patent Claims

rsspad.com     Mar 7, 2008          

Euroscreen SA today announced its success in its patent battle against Progenics Inc. (PRWeb Mar 7, 2008) Read the full story at ... Euroscreen SA today announced its success in its patent battle against Progenics Inc. Brussels, Belgium March 7, 2008 -- Euroscreen SA...                    

comments

Adolor Under the FDA's Spotlight (at Motley Fool)

yahoo.com     Feb 23, 2008   2 related          

By Brian Lawler January 22, 2008 Drugmaker Adolor (Nasdaq: ADLR) got a bit of surprising good news from the FDA on Friday, only a few weeks ahead of an upcoming FDA decision on whether to approve the company's lead drug. In the document, which was released prior to the...                    

comments